AbCellera Biologics (ABCL) Research & Development (2020 - 2026)
AbCellera Biologics (ABCL) posted Research & Development of $46.7 million for Q1 2026, down 6.85% on a QoQ basis from $50.1 million in Q4 2025, and up 9.8% year-over-year from $42.5 million in Q1 2025.
AbCellera Biologics (ABCL) Research & Development (2020 - 2026) Analysis & Trends
AbCellera Biologics' Research & Development history runs 7 years deep, the most recent figure standing at $46.7 million for Q1 2026.
- Quarterly Research & Development rose 9.8% year-over-year to $46.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.9 million (down 32.71% YoY) and the FY2025 annual result came in at $186.8 million, up 11.7% from the prior year.
- Research & Development was $46.7 million for Q1 2026 at AbCellera Biologics, down from $50.1 million in the prior quarter.
- Across five years, Research & Development topped out at $157.6 million in Q4 2024 and bottomed at $2.9 million in Q3 2025.
- A 5-year average of $39.3 million and a median of $37.9 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 1960.62% — and 2024, when it sank 91.73%.
- AbCellera Biologics' Research & Development stood at $28.2 million in 2022, then jumped by 72.14% to $48.6 million in 2023, then soared by 224.18% to $157.6 million in 2024, then tumbled by 68.22% to $50.1 million in 2025, then declined by 6.85% to $46.7 million in 2026.
- Business Quant data shows ABCL's Research & Development at $46.7 million in Q1 2026, $50.1 million in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | AbCellera Biologics | 1.72 Bn | 1.72 Bn | - | 46.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.66 Mn |
| Dec 31, 2025 | 50.09 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | 39.21 Mn |
| Mar 31, 2025 | 42.50 Mn |
| Dec 31, 2024 | 157.62 Mn |
| Sep 30, 2024 | 3.14 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Mar 31, 2024 | 39.29 Mn |
| Dec 31, 2023 | 48.62 Mn |
| Sep 30, 2023 | 37.92 Mn |
| Jun 30, 2023 | 36.47 Mn |
| Mar 31, 2023 | 52.65 Mn |
| Dec 31, 2022 | 28.25 Mn |
| Sep 30, 2022 | 26.58 Mn |
| Jun 30, 2022 | 26.69 Mn |
| Mar 31, 2022 | 26.37 Mn |
| Dec 31, 2021 | 56.98 Mn |
| Sep 30, 2021 | 17.45 Mn |
| Jun 30, 2021 | 1.30 Mn |